Shimadzu Corporation, a global leader in the precision instrumentation industry, and Diagnostics Development Hub (DxD Hub), a national platform hosted by Singapore’s Agency for Science, Technology and Research (A*STAR), are pleased to announce a strategic collaboration to establish the Shimadzu – DxD Hub Diagnomics Centre (SDDC) at Biopolis, Singapore. Officially launched today, the SDDC will drive innovation and accelerate the development of diagnostic products by integrating Shimadzu’s technological expertise with DxD Hub’s productisation platforms.

VUMC has been awarded up to $30 million from the Advanced Research Projects Agency for Health (ARPA-H) to build a massive antibody-antigen atlas, develop AI-based algorithms to engineer antigen-specific antibodies, and apply the AI technology to identify and develop potential therapeutic antibodies.

The critical role of EZH2, an essential epigenetic regulator, in cancer progression and treatment is underscored in this new review article published in Genes & Diseases. The study highlights the transformative potential of EZH2 inhibition, paving the way for a new generation of targeted therapies aimed at disrupting tumor growth and overcoming treatment resistance.

This review highlights the critical role of ubiquitination in governing the functionality of cancer stem cells (CSCs), shedding light on potential therapeutic targets for combating tumor progression, recurrence, and drug resistance. Published in Genes & Diseases, this article explores the intricate mechanisms through which the ubiquitin (Ub) system regulates key pathways essential for CSC maintenance and survival.

Lung cancer remains one of the leading causes of cancer-related mortality, with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) representing the most prevalent subtypes of non-small cell lung cancer (NSCLC). Despite their classification under the same umbrella, these two forms of lung cancer exhibit distinct genetic landscapes, therapeutic targets, and treatment responses.

A new review article highlights the transformative role of circular RNA (circRNA) in cancer, revealing its potential as both a key player in tumor biology and a promising avenue for future therapies. Once thought to be noncoding RNA, circRNA has now been shown to encode functional proteins, challenging conventional RNA biology and opening up novel therapeutic possibilities.